Category Archives: high priced drugs

Bayh-Dole march-in won’t change drug prices but other things might–2

Now let’s look at alternatives to Bayh-Dole’s march-in procedures to address competition, public access, and prevention of unreasonable use, including price gouging. We will consider two within Bayh-Dole and two outside Bayh-Dole. The Bayh-Dole alternatives are: use the government license … Continue reading

Posted in Bayh-Dole, high priced drugs, Policy | Tagged , , , , | Comments Off on Bayh-Dole march-in won’t change drug prices but other things might–2

Bayh-Dole march-in won’t change drug prices but other things might–1

Folks think that somehow Bayh-Dole permits government take over of pharma patents and by doing this, somehow, the price of drugs will necessarily–magically–go down. Let’s work through this idea. Set aside for a moment that many drugs don’t do much … Continue reading

Posted in Bayh-Dole, high priced drugs, Policy | Tagged , , , , | Comments Off on Bayh-Dole march-in won’t change drug prices but other things might–1

Bayh-Dole government-wide licenses

In a Twitter thread in which Jennifer Gunter argues that “Americans should not be bankrolling the pharmaceutical industry,” Steven Martin tweets Let’s work this through. There is no need to revise Bayh-Dole for state and municipal governments to authorize the … Continue reading

Posted in Bayh-Dole, high priced drugs | Tagged , , , | Comments Off on Bayh-Dole government-wide licenses